Permali Gloucester has been acquired by Diamorph
Private equity firm 3i Group and the private shareholders of Permali Gloucester Limited have sold their interest in the company to Diamorph.
Permali Gloucester is a leading designer and manufacturer of composite and thermoplastic polyurethane (TPU) material solutions. It serves global OEMs and government organizations across a wide range of sectors, including defense, aerospace, Formula One (F1), medical and rail, supplying bespoke and highly technical products for often mission critical applications.
Diamorph provides material solutions under a range of brands for highly demanding environments and is backed by Epiris LLP, an independent private equity firm. The addition of Permali’s strong positions in defense, medical and F1 to the Diamorph Wear Components business unit, with the two businesses’ adjacent technology bases, will strengthen the group and create a significant UK player in laminate-based composite materials.
Oaklins Smith & Williamson, based in the UK, with the support of the team in Irvine, California, worked with the shareholders of Permali Gloucester Limited to deliver a successful sale to a strategic partner that can use Permali’s Gloucester (UK) base as the center of excellence for developing and growing its enlarged composites offering.



Gus King
Former Managing Director and major shareholder, Permali Gloucester Limited
Talk to the deal team


Brian Livingston
Managing Director
London, United KingdomOaklins Smith & Williamson

Stephen Perry
Managing Director
Irvine, United StatesOaklins Janes Capital

Carolina Coquim
Associate
London, United KingdomOaklins Smith & Williamson
Related deals
Matera has acquired a majority stake in Onidata Tecnologia
Matera has acquired a majority stake in Onidata Tecnologia.
Learn moreFrediani has been acquired by The Florence Group
The Frediani family have sold Frediani S.r.l. to The Florence Group.
Learn moreSerenis and three other independent clinics have acquired Clinique du Chateau de Vernhes
Groupe Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes from the funding family.
Learn more